Cargando…

An Exploratory Study of Itolizumab on the Preservation of Beta Cell Function in Adults with Recent-Onset Type 1 Diabetes

We conducted a phase I-IIa, randomized, monocentric, double-blind, placebo-controlled clinical trial to evaluate the safety and impact of the combination treatment of Itolizumab and insulin on preserving beta cell function in adults with recent-onset type 1 diabetes. Twelve patients were randomly as...

Descripción completa

Detalles Bibliográficos
Autores principales: Cabrera-Rode, Eduardo, Cubas-Dueñas, Ileana, Rodríguez-Acosta, Janet, García-García, Yudith, Torres-López, Yelena, Prieto-Noa, Claudia, Vázquez-Izada, Bárbara M., Ruíz-Reinoso, Maité, Echevarría-Valdés, Ragmila, Álvarez-Álvarez, Aimee, Domínguez-Alonso, Emma, Conesa-González, Ana Ibis, González-Calero, Teresa, Robles-Torres, Erick, Turcios-Tristá, Silvia Elena, Senra-Estévez, Elizabeth, Hernández-Casaña, Patricia, Sarmiento, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999981/
https://www.ncbi.nlm.nih.gov/pubmed/35407396
http://dx.doi.org/10.3390/jcm11071789
_version_ 1784685321229697024
author Cabrera-Rode, Eduardo
Cubas-Dueñas, Ileana
Rodríguez-Acosta, Janet
García-García, Yudith
Torres-López, Yelena
Prieto-Noa, Claudia
Vázquez-Izada, Bárbara M.
Ruíz-Reinoso, Maité
Echevarría-Valdés, Ragmila
Álvarez-Álvarez, Aimee
Domínguez-Alonso, Emma
Conesa-González, Ana Ibis
González-Calero, Teresa
Robles-Torres, Erick
Turcios-Tristá, Silvia Elena
Senra-Estévez, Elizabeth
Hernández-Casaña, Patricia
Sarmiento, Luis
author_facet Cabrera-Rode, Eduardo
Cubas-Dueñas, Ileana
Rodríguez-Acosta, Janet
García-García, Yudith
Torres-López, Yelena
Prieto-Noa, Claudia
Vázquez-Izada, Bárbara M.
Ruíz-Reinoso, Maité
Echevarría-Valdés, Ragmila
Álvarez-Álvarez, Aimee
Domínguez-Alonso, Emma
Conesa-González, Ana Ibis
González-Calero, Teresa
Robles-Torres, Erick
Turcios-Tristá, Silvia Elena
Senra-Estévez, Elizabeth
Hernández-Casaña, Patricia
Sarmiento, Luis
author_sort Cabrera-Rode, Eduardo
collection PubMed
description We conducted a phase I-IIa, randomized, monocentric, double-blind, placebo-controlled clinical trial to evaluate the safety and impact of the combination treatment of Itolizumab and insulin on preserving beta cell function in adults with recent-onset type 1 diabetes. Twelve patients were randomly assigned to three treatment groups, each receiving a different Itolizumab dose (0.4/0.8/1.6 mg/kg body weight, respectively) and a placebo group. All patients received concomitant intensive multiple-dose insulin therapy. Endogenous insulin secretion was assessed by the measurement of C-peptide during the mixed-meal tolerance test. No serious adverse events were reported. No changes in the total daily insulin doses, glycated hemoglobin levels, and stimulated C-peptide were observed between the Itolizumab and placebo groups at 52 weeks. A significant decrease in stimulated C-peptide was observed during the follow-up period (p = 0.012). One subject treated with 1.6 mg of Itolizumab showed a marked increase in the levels of stimulated C-peptide three years after completion of the trial. Taken together, this is the first study to demonstrate that combination treatment with Itolizumab and insulin is safe in humans and does not affect the residual function of beta cells up to 52 weeks. The findings from our study show preliminary evidence that high doses of Itolizumab could potentially arrest the loss of beta cell function in the long term. Further studies with a longer follow-up and larger numbers of patients are envisaged to assess the effect with high dose Itolizumab.
format Online
Article
Text
id pubmed-8999981
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89999812022-04-12 An Exploratory Study of Itolizumab on the Preservation of Beta Cell Function in Adults with Recent-Onset Type 1 Diabetes Cabrera-Rode, Eduardo Cubas-Dueñas, Ileana Rodríguez-Acosta, Janet García-García, Yudith Torres-López, Yelena Prieto-Noa, Claudia Vázquez-Izada, Bárbara M. Ruíz-Reinoso, Maité Echevarría-Valdés, Ragmila Álvarez-Álvarez, Aimee Domínguez-Alonso, Emma Conesa-González, Ana Ibis González-Calero, Teresa Robles-Torres, Erick Turcios-Tristá, Silvia Elena Senra-Estévez, Elizabeth Hernández-Casaña, Patricia Sarmiento, Luis J Clin Med Communication We conducted a phase I-IIa, randomized, monocentric, double-blind, placebo-controlled clinical trial to evaluate the safety and impact of the combination treatment of Itolizumab and insulin on preserving beta cell function in adults with recent-onset type 1 diabetes. Twelve patients were randomly assigned to three treatment groups, each receiving a different Itolizumab dose (0.4/0.8/1.6 mg/kg body weight, respectively) and a placebo group. All patients received concomitant intensive multiple-dose insulin therapy. Endogenous insulin secretion was assessed by the measurement of C-peptide during the mixed-meal tolerance test. No serious adverse events were reported. No changes in the total daily insulin doses, glycated hemoglobin levels, and stimulated C-peptide were observed between the Itolizumab and placebo groups at 52 weeks. A significant decrease in stimulated C-peptide was observed during the follow-up period (p = 0.012). One subject treated with 1.6 mg of Itolizumab showed a marked increase in the levels of stimulated C-peptide three years after completion of the trial. Taken together, this is the first study to demonstrate that combination treatment with Itolizumab and insulin is safe in humans and does not affect the residual function of beta cells up to 52 weeks. The findings from our study show preliminary evidence that high doses of Itolizumab could potentially arrest the loss of beta cell function in the long term. Further studies with a longer follow-up and larger numbers of patients are envisaged to assess the effect with high dose Itolizumab. MDPI 2022-03-24 /pmc/articles/PMC8999981/ /pubmed/35407396 http://dx.doi.org/10.3390/jcm11071789 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Cabrera-Rode, Eduardo
Cubas-Dueñas, Ileana
Rodríguez-Acosta, Janet
García-García, Yudith
Torres-López, Yelena
Prieto-Noa, Claudia
Vázquez-Izada, Bárbara M.
Ruíz-Reinoso, Maité
Echevarría-Valdés, Ragmila
Álvarez-Álvarez, Aimee
Domínguez-Alonso, Emma
Conesa-González, Ana Ibis
González-Calero, Teresa
Robles-Torres, Erick
Turcios-Tristá, Silvia Elena
Senra-Estévez, Elizabeth
Hernández-Casaña, Patricia
Sarmiento, Luis
An Exploratory Study of Itolizumab on the Preservation of Beta Cell Function in Adults with Recent-Onset Type 1 Diabetes
title An Exploratory Study of Itolizumab on the Preservation of Beta Cell Function in Adults with Recent-Onset Type 1 Diabetes
title_full An Exploratory Study of Itolizumab on the Preservation of Beta Cell Function in Adults with Recent-Onset Type 1 Diabetes
title_fullStr An Exploratory Study of Itolizumab on the Preservation of Beta Cell Function in Adults with Recent-Onset Type 1 Diabetes
title_full_unstemmed An Exploratory Study of Itolizumab on the Preservation of Beta Cell Function in Adults with Recent-Onset Type 1 Diabetes
title_short An Exploratory Study of Itolizumab on the Preservation of Beta Cell Function in Adults with Recent-Onset Type 1 Diabetes
title_sort exploratory study of itolizumab on the preservation of beta cell function in adults with recent-onset type 1 diabetes
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999981/
https://www.ncbi.nlm.nih.gov/pubmed/35407396
http://dx.doi.org/10.3390/jcm11071789
work_keys_str_mv AT cabrerarodeeduardo anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT cubasduenasileana anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT rodriguezacostajanet anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT garciagarciayudith anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT torreslopezyelena anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT prietonoaclaudia anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT vazquezizadabarbaram anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT ruizreinosomaite anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT echevarriavaldesragmila anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT alvarezalvarezaimee anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT dominguezalonsoemma anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT conesagonzalezanaibis anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT gonzalezcaleroteresa anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT roblestorreserick anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT turciostristasilviaelena anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT senraestevezelizabeth anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT hernandezcasanapatricia anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT sarmientoluis anexploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT cabrerarodeeduardo exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT cubasduenasileana exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT rodriguezacostajanet exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT garciagarciayudith exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT torreslopezyelena exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT prietonoaclaudia exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT vazquezizadabarbaram exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT ruizreinosomaite exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT echevarriavaldesragmila exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT alvarezalvarezaimee exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT dominguezalonsoemma exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT conesagonzalezanaibis exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT gonzalezcaleroteresa exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT roblestorreserick exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT turciostristasilviaelena exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT senraestevezelizabeth exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT hernandezcasanapatricia exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes
AT sarmientoluis exploratorystudyofitolizumabonthepreservationofbetacellfunctioninadultswithrecentonsettype1diabetes